Shutting down a single immune signaling pathway reduced brain inflammation, protected neurons and improved movement in a humanized mouse model of Huntington disease, according to a study from Florida Atlantic University and collaborators published in the Proceedings of the National Academy of Sciences. The pathway, known as cGAS-STING, now stands out as a candidate target for drugs aimed at slowing the disease rather than simply easing its symptoms.
The cGAS-STING pathway is part of the body's built-in defense system. A protein called cGAS acts as a sensor for damaged or misplaced DNA inside cells, which can happen during infection, stress or disease. When it detects that abnormal DNA, cGAS produces a signaling molecule called cGAMP, which switches on a second protein, STING. Activated STING then turns on inflammatory and immune-response genes. Useful in an infection, that same alarm system appears to run destructively long in the Huntington brain.
That matters because Huntington disease, caused by a mutation in the huntingtin gene, progressively kills nerve cells and erodes coordination, memory, mood and clear thinking. Existing treatments manage symptoms; none slow or stop the underlying course of the illness, which is ultimately fatal. Mounting evidence has implicated chronic brain inflammation as a major driver of that decline, and these results give researchers a specific molecular lever behind it rather than a general sense that inflammation is involved.
The work was done in mice, so the immediate value is directional: it identifies where to aim, not a treatment ready for patients. Interest in cGAS-STING extends well beyond Huntington disease, since chronic inflammatory signaling in the brain features in a range of neurodegenerative conditions - which makes any pathway shown to be both drivable and blockable worth watching closely.